NEW YORK, Sept. 21 /PRNewswire/ -- Emissary Capital Group, Inc. has initiated investment research coverage on Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) with a Buy rating and target price of $1.00-$1.25. Jiangsu, China-based SNBP, known domestically as Dong Ying Pharmaceutical Co. Ltd., is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products. The company focuses primarily on the development of anesthesia-assisted agents as well as antibiotics for penicillin-allergic patients and cardiovascular-related products related to high blood pressure (commercial in October 2009). KuTai, SNBP's flagship product is a first-to-market Cisatracurium Besylate injectable that serves as a low cost skeletal muscle relaxant used during pre-surgical and surgical procedures. The company holds five patents in Chiral Pharmaceutical Ingredient Synthesis and Purification, and Molecular Packaging Formulation (see proprietary technology section) and has the longer-term ability to expand both the breadth of its product line and market share through R&D partnerships with Cornell University, Nanjing University, China Pharmaceutical University, and Nanjing Medical University.
About Emissary Capital Group
Emissary Capital Group, Inc. is a New York City-based company that provides strategic consulting and research services to emerging growth companies primarily based in India and China. The firm provides a diversified array of services to small and medium sized private companies, generally defined as those with annual revenues under $200 million, in order to assist them to become publicly traded companies in the U.S. For more information, please visit www.emissarycapital.com
Contact: Albert Lee Emissary Capital Group, LLC 1-212-297-6218
|SOURCE Emissary Capital Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved